| 1.19 0 (0%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.85  |
1-year : | 2.21 |
| Resists | First : | 1.58 |
Second : | 1.89 |
| Pivot price | 1.22 |
|||
| Supports | First : | 1.07 | Second : | 0.89 |
| MAs | MA(5) : | 1.18 |
MA(20) : | 1.31 |
| MA(100) : | 2.32 |
MA(250) : | 3.1 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 24.4 |
D(3) : | 22.2 |
| RSI | RSI(14): 30.6 | |||
| 52-week | High : | 5.5 | Low : | 1.07 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AKTX ] has closed above bottom band by 40.5%. Bollinger Bands are 31.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.2 - 1.21 | 1.21 - 1.21 |
| Low: | 1.16 - 1.16 | 1.16 - 1.17 |
| Close: | 1.18 - 1.19 | 1.19 - 1.2 |
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
Mon, 15 Apr 2024
Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024 - GlobeNewswire
Tue, 02 Apr 2024
Insiders Who Purchased US$1.43m Of Akari Therapeutics Stock May Not Have Expected 21% Tumble - Simply Wall St
Mon, 01 Apr 2024
Akari Therapeutics Insider Ups Holding By 69% During Year - Yahoo Finance
Mon, 01 Apr 2024
Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights - Yahoo Finance
Tue, 05 Mar 2024
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AKTX, HES, TGAN, NS - PR Newswire
Tue, 05 Mar 2024
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline ... - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 9.56e+009 (%) |
| Held by Institutions | 17.9 (%) |
| Shares Short | 10 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.68e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -115.6 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 293.15 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -28.57 |
| Dividend | 0 |
| Forward Dividend | 5950 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|